Recruiting
Phase 1

INCB057643

Sponsor:

Incyte Corporation

Code:

NCT04279847

Conditions

Myelofibrosis

Myelodysplastic Syndrome

Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome

Myeloproliferative Neoplasm

Relapsed or Refractory Primary Myelofibrosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

INCB057643

Ruxolitinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-23. This information was provided to ClinicalTrials.gov by Incyte Corporation on 2025-09-12.